As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past

Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.

Syringes stuck in a dartboard

Since Amgen Inc. and Novartis AG are likely to have the first CGRP inhibitor on the market with Aimovig (erenumab), the partners will have an important opportunity to set the pricing and reimbursement tone for the class of migraine therapies, which ultimately will determine whether Aimovig lives up to the hype or becomes a PCSK9-like disappointment.

Amgen CEO Bob Bradway said on the company’s April 24 first quarter earnings call that the company expects to launch...

More from Drug Pricing

More from Scrip

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.